NL-OMON22893已完成不适用
A preference trial with naratriptan 2,5 mg and paracetamol 1000 mg in migraine patients in the general practice.
未提供0 个研究点目标入组 40 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. The subject is older than 18 years of age at visit 1;
- •2. The subject has a current history of migraine with or without aura according to the IHS criteria;
排除标准
- •1. Subjects with a history suggestive of ischemic heart disease (IHD), (e.g. angina pectoris) or any atherosclerotic disease which places them at increased risk of coronary ischaemia;
- •2. Subjects with a history of cerebrovascular accident (CVA) or transient ischaemic attack (TIA);
研究者
相似试验
已完成
不适用
A preference trial with naratriptan 2.5 mg and paracetamol 1000 mg in migraine patients in the general practiceNervous System DiseasesMigraineISRCTN57387771eiden University Medical Centre (LUMC) (The Netherlands)40
撤回
3 期
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.HeadacheMigraineNCT01726920Ache Laboratorios Farmaceuticos S.A.
已完成
不适用
Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted ConditionsMigraineNCT01161667Roxane Laboratories35
已完成
不适用
Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed ConditionsMigraineNCT01161654Roxane Laboratories33
撤回
3 期
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of MigraineHeadacheMigraineNCT01390324Ache Laboratorios Farmaceuticos S.A.